Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-Jaktinib in Healthy Chinese Males
NCT05150717Phase 1Completed
- Sponsor
- Zelgen
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of jaktinib in myelofibrosis (MF), sponsored by Zelgen. Primary endpoints: Cumulative excretion of 14C-labeled drug-related material and Proportion of different metabolites. Started Jan 2022; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05150717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150717.